443
Participants
Start Date
August 17, 2022
Primary Completion Date
November 18, 2024
Study Completion Date
July 8, 2025
BMF-219
Investigational Product
IMA Clinical Research Manhattan, New York
Omera Health, Brooklyn
Manassas Clinical Research, Manassas
Wake Forest Health Network, LLC, Medical Plaza, Winston-Salem
Carolina Research Center, Shelby
David Kavtaradze MD, Inc, Cordele
Privia Medical Group, Savannah
G+C Research Group, Hialeah
Panax Clinical Research, Miami Lakes
Sunbright Health Research Centers, Homestead
Avantis Clinical Research, Miami
Century Research LLC, Miami
Entrust Clinical Research, Miami
Southwest General Healthcare Center, Fort Myers
Medical Care, LLC, Elizabethton
Diabetes and Endocrinology Associates of Stark County, Canton
Cedar Crosse Research Center, Chicago
IMA Clinical Research St. Louis, St Louis
Velocity Clinical Research, Dallas
Zenos Clinical Research, Dallas
Velocity Clinical Research, Waco
Synergy Groups Medical LLC, Houston
Synergy Group Medical, Houston
Synergy Group Medical, Missouri City
Simcare Medical Research, Sugar Land
Clinical Trials of Texas, LLC, San Antonio
Diabetes & Glandular Disease Clinic, P.A., San Antonio
IMA Clinical Research, Austin
Velocity Clinical Research, Jordan
Santa Rosa Medical Centers of Nevada, Las Vegas
Ark Clinical Research, Long Beach
Hope Clinical Research, Canoga Park
Catalina Research Institute, LLC, Montclair
Velocity Clinical Research, La Mesa
Metro Clinical Trials, San Bernardino
Ark Clinical Research, LLC, Fountain Valley
BC Diabetes, Vancouver
Centricity Research LMC, Toronto
BioPharma Services Inc., Toronto
Lead Sponsor
Biomea Fusion Inc.
INDUSTRY